Amendments for: 172-2021-2022-Q1-972253

Agreement Value: $1,000,000.00
Agreement: Infrastructure capacity modification to support cGMP-compliant manufacture of lentiviral vectors at CETC (972253). Apr 1, 2021 - Mar 31, 2025
Description:

This Project aims at establishing a current Good Manufacturing Practices (cGMP)-compliant platform to manufacture clinical grade lentiviral vectors (including production, purification and quality control) at the Centre of Excellence for Cellular Therapy (CETC) of Hôpital Maisonneuve-Rosemont. It builds on the capacity of the CETC, the only fully operational cGMP-compliant cell therapy facility in Canada, to generate viral vectors of clinical and commercial grade at the 50L scale.
The Project involves: 1) generating the documentation during its purchase, 2) its qualification, 3) validation of the manufacture process, and 4) training and knowledge dissemination. At the end of the Project, a fully functional cGMP- compliant viral vector production manufacturing platform will be available in Canada to ensure accessibility of affordable cell and gene therapies for Canadians.

Expected Results:

In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.

Organization: National Research Council Canada
Recipient: Centre for Commercialization of Cancer Immunotherapy (Not-for-profit organization or charity)
Location: Montreal, Quebec, CA H1T 2M4
Type: Contribution
Additional Information:

This agreement has been amended 2 time(s). The end date of this agreements has been modified by 639 days.

Federal Riding Name: Hochelaga (24028)
Program Name: Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives

Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.

NAICS Code: 541710

Agreement Value:
Organization: National Research Council Canada
Recipient: -
Type: -
Additional Information:

This agreement has been amended 2 time(s). The end date of this agreements has been modified by 639 days.

NAICS Code: 541710

Agreement Value:
Agreement: Infrastructure capacity modification to support cGMP-compliant manufacture of lentiviral vectors at CETC - Jun 30, 2023
Organization: National Research Council Canada
Recipient: -
Type: -
Additional Information:

This agreement has been amended 1 time(s). The end date of this agreements has been modified by 121 days

Agreement Value: $1,000,000.00
Agreement: Infrastructure Capacity Modification to Support cGMP-Compliant Manufacture of Lentiviral Vectors at CETC. (972253). Apr 1, 2021 - Mar 31, 2023
Description:

This Project aims at establishing a current Good Manufacturing Practices (cGMP)-compliant platform to manufacture clinical grade lentiviral vectors (including production, purification and quality control) at the Centre of Excellence for Cellular Therapy (CETC) of Hôpital Maisonneuve-Rosemont. It builds on the capacity of the CETC, the only fully operational cGMP-compliant cell therapy facility in Canada, to generate viral vectors of clinical and commercial grade at the 50L scale.
The Project involves: 1) generating the documentation during its purchase, 2) its qualification, 3) validation of the manufacture process, and 4) training and knowledge dissemination. At the end of the Project, a fully functional cGMP- compliant viral vector production manufacturing platform will be available in Canada to ensure accessibility of affordable cell and gene therapies for Canadians.

Expected Results:

In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.

Organization: National Research Council Canada
Recipient: Centre for Commercialization of Cancer Immunotherapy (Not-for-profit organization or charity)
Location: Montreal, Quebec, CA H1T 2M4
Type: Contribution
Federal Riding Name: Hochelaga (24028)
Program Name: Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives

Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.

NAICS Code: 541710 - R&D in the physical, engineering and life sciences